IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)

Dr. Jack West reviews the IMpower133 trial that integrated atezolizumab with first line chemo for extensive stage SCLC and discusses whether the results improve outcomes enough to change our standard of care in this setting.

IMpower133, atezolizumab,  first line chemo, extensive stage SCLC